New attack on rare nerve disease tests faster steroid withdrawal

This study is testing a drug called inectolizumab (inebilizumab) in people experiencing their first attack of neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease that damages the nerves. The main goal is to see if the drug allows patients to safely stop taking high-dose steroids more quickly, while also helping improve their disability. Researchers will compare a faster steroid-tapering schedule to a standard one in 25 new patients.